Skip to main content
. Author manuscript; available in PMC: 2021 Oct 11.
Published in final edited form as: Biotechnol Bioeng. 2020 Jul 9;117(10):3066–3080. doi: 10.1002/bit.27479

Figure 3. Cisplatin-resistant OVCAR-3 cells have higher tolerance for immobilization and silica gel environment.

Figure 3.

(A) Cells retreated with a second dose of cisplatin are less susceptible to treatment than cells undergoing primary treatment, indicating the first dose selected for cisplatin-resistant cells. Each treatment dose was 0.5 μM cisplatin for 24 hours, and cells receiving a second dose were allowed a 2-week recovery period before treatment with the second dose. Viable cell number at Day 0 is the number of live cells counted immediately after drug removal. (*P < 0.05 compared to “First Dose”). (B) Cisplatin-resistant cells (“Treated”, i.e. treated with cisplatin and allowed to recover for 2 weeks) have similar Ki67 expression level as untreated cells. (C) Fold change in viable cell number relative to Day 0 of immobilized cisplatin-resistant cells and untreated control cells (*P < 0.05 compared to “Control” at each timepoint).